MGI gene sequencing company

Location: Home /  News Center

MOU signed between BGI and Xing Technologies on Research Collaboration and Innovation of Cutting-edge Life Sciences Technology

Release date:2018-08-22Writer:MGIViews:1041Share

The bio-nanotechnology innovator Xing Technologies (hereinafter “XING”) is a UQ spin-off enterprise specialising in world-leading disease diagnosis and monitoring technologies, including cancer. Its proprietary nano-technologies are transforming the future practice of medicine and healthcare.

BGI, a global genomics giant, is the largest organisation in the world in genomics research and applications. With its strong technological capabilities and expertise in gene sequencing and instrument development, BGI adds significant value to the partnership to conduct joint research and develop revolutionary medical and healthcare products for the people in Australia and the rest of the world.

A Memorandum of Understanding (MOU) between two parties is signed (TODAY) supporting collaborative research and product innovation in the following areas:

●DNB technology: optimise current DNA nanoball technology to improve sequencing data quality and throughput resulting in reduced sequencing costs;

● Circulating Tumour/Stem Cells (CTC) technology (cells shed from a primary tumour that disseminate in the body’s circulatory system): integrate CTC isolation, characterisation and sequencing for fast and accurate disease screening and monitoring;

● Point-of-care product: based on XING’s patented “Laboratory in a Drop” technology, undertake joint research into, and manufacturing of, a transformative diagnostic product developed by XING to offer the world, including millions of Australians, an accurate, rapid and inexpensive point-of-care disease screening, diagnosis & monitoring kit, which will revolutionise current practice. The applications even extend to human health as well as animals and plant material, such as agriculture, aquaculture, veterinary science.

As part of the collaboration, BGI has placed a BGISEQ-500 genetic sequencer, supplied by MGI-a subsidiary of BGI manufacturing proprietary sequencers and related instrumentation, at the XING’s laboratory in Brisbane.

Dr Paul Mainwaring, Chief Medical Officer of XING, expressed his delight and optimism in respect of the collaboration with BGI. “BGI and XING share a common vision to dramatically improve health outcomes for people around the world. Our partnership promises to leverage technology and deliver scale to truly transform the health sector. We are honoured to be working in close relationship with BGI, a global leader in this field”

Mr. Duncan YU, BGI’s Vice President and MGI’s President says “we are very excited about the collaboration. The joint effort of expertise in nanotechnology and genomics will lead to innovations in delivering better health package. We are looking forward to making point-of-care products available for the global users.”

Since the BGI Australia office opened in 2016, BGI has initiated projects covering a wide range of areas via partnerships with strong local scientific research partners, such as imaging and genomics cancer, infectious disease, marine biology and biodiversity. For more information on BGI Australia please visit here.

BGI Australia Media Contact:

Stephanie Sun T:   +61 7 3362 0475 M: +61 4 2778 8574 Email:

Quick Contact